Experimental Hematology & Oncology

Papers
(The H4-Index of Experimental Hematology & Oncology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity292
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia213
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis212
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting175
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD153
Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma144
From Amphiphiles to mRNA platforms: emerging vaccination strategies for pancreatic cancer137
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience133
Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmu127
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities126
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux117
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies114
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms104
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer103
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics99
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy98
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside96
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling93
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives85
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review82
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma79
HIV associated lymphoma: latest updates from 2023 ASH annual meeting79
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone75
Tetrahydromagnolol targets TRIM38 to mediate PANoptosis in cancer cells and has the potential for synergistic cancer therapy75
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers68
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy66
Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis65
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy59
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma59
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response58
Enhanced cellular therapy: revolutionizing adoptive cellular therapy56
ISX–TWIST1 reprograms CD47–inflammasome signaling to reshape the immune microenvironment in liver cancer55
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways54
Breast cancer heterogeneity and its implication in personalized precision therapy54
Role of m6A writers, erasers and readers in cancer54
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies54
Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting54
Three-dimensional chromatin landscapes in MLLr AML52
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma52
The novel retinoid WYC-209 sensitizes multiple myeloma to carfilzomib via epigenetically upregulating ZMYND851
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting51
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study50
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia49
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma48
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells48
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma48
Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK+ ALCL47
0.1314389705658